Genome Engineering Market worth $11.7 Billion by 2026
According to research report the global Genome Engineering Market is projected to reach $11.7 billion by 2026 from USD 5.1 billion in 2021, at a CAGR of 18.2 % between 2021 and 2026.
The
key factors propelling the growth of this market are rising government
funding and growth in the number of genomics projects, high prevalence
of infectious diseases and cancer, technological advancements,
increasing production of genetically modified crops, and growing
application areas of genomics.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000
The
technology segment of the genome editing market is classified into
CRISPR, TALEN, ZFN, antisense, and other technologies (PiggyBac, Flp-In,
Adenine Base Editor (ADE), and Jump-In). The CRISPR segment is expected
to command the largest share of the global genome editing market in.
The large share of this segment can be attributed to the potential
advantage of CRISPR is its ability to multiplex, that is, to use
multiple guide RNAs in parallel to target multiple sites simultaneously
in the same cell, making it easier to mutate multiple genes at once or
engineer precise deletions in a genomic region.
By application,
the genome editing market is segmented into cell line engineering,
genetic engineering, and other applications (diagnostics and
therapeutics). The cell line engineering segment is estimated to account
for the largest share of the global market. Growing industry focus on
stem cell research, increasing global awareness about stem cell
therapies, and increasing funding from governments and private
organizations are driving the growth of the cell line engineering
segment.
By end user, the genome editing market is segmented into
biotechnology & pharmaceutical companies, academic & government
research institutes, and contract research organizations. The
biotechnology & pharmaceutical companies segment is estimated to
account for the largest share of the global genome editing market. The
increasing prevalence of infectious diseases and cancer are driving
research activities worldwide; this is expected to drive the demand for
genome editing in biotechnology & pharmaceutical companies.
Request For Report Sample pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=231037000
North
America is expected to dominate the global genome editing market.
Factors such as increasing use of genetically modified crops, the
development of gene therapy in the US, rising prevalence of infectious
diseases and cancer, and rising availability of research grants and
funding are propelling market growth in North America.
Some of
the major players in the market are Thermo Fisher Scientific (US),
Merck (Germany), Horizon Discovery Group (UK), GenScript (US), Sangamo
BioSciences (US), Integrated DNA Technologies (US), Lonza Group
(Switzerland), New England Biolabs (US), OriGene Technologies (US),
Transposagen Biopharmaceuticals (US), Editas Medicine (US), and CRISPR
Therapeutics (Switzerland).
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
sales@marketsandmarkets.com
Comments
Post a Comment